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Treatment of mI-labelled high-density lipoprotein (["~I]HDL,) with monospoeific polyclonal antibodies against apolipoproteins A-I and A-II 
resulted in a dose-dependent i hibition of the [~-"~I]HDL.~ binding to isolated human small intestine pithelial cells by 25% and 50%, respectively, 
Both antibodies also inhibited intracellular degradation of [mlIHDL.~ by 80%. Treatment of enterocytes with polyclonal antibody against 
apolipoprotein A-I binding protein, a putative HDL receptor, inhibited both binding and degradation of [mlIHDL~ by these cells by 50%, 
Antibodies to apolipoprotein A-I, A.II and ape A-l-binding protein also inhibited ['"~I]HDLa binding to cholesterol-loaded c lls, 
Apolipoprotein A.I; Apolipoprotein A.II; High-density lipoprotein receptor; Human ¢nterocyte 
I. INTRODUCTION 
Putative high-density l ipoprotein (HDL)  receptors 
have been demonstrated on several types o f  human and 
animal cells [1] including small intestine pithelial cells 
(enterocytes) [2--4]. Despite attempts to identify which 
component(s) o f  HDL  interact with its receptor, the 
exact nature of  the ligand remains controversial, Al- 
though most evidence supports the role o f  apolipopro- 
teins as ligands [5,6], conflicting data still exist regard- 
ing which protein is involved in the interaction, and 
different laboratories reported that apol ipoproteins 
(ape) A-I (ape A.I)  [6], ape A-II [5], A-IV [6] and C [6] 
may be determinants of  HDL  binding. 
Proteins which specifically bind ape A-I and HDL 
have been isolated and partially characterized from a 
number of cells, These proteins may represent the puta- 
tive HDL receptor or parts thereof [7-10]. One of  these 
proteins, isolated from human placenta by affinity 
chromatography,  specifically bound to ape A-I and was 
designated as ape A-I-binding protein (ape A-I-BP) [9]. 
In the present study we have used ant ibody against 
ape  A-I, ape A-If and ape A-I-BP to further investigate 
which proteins are involved in the interaction of  HDL  
with human enterocytes, 
Abbreviations: ape A-I, apolipoprotein A-I; ape A-II, apolipoprotein 
A-II; ape A-I.BP, apolipoprotein A-l-binding protein; HDL, high- 
density lipoprotein; LDS, lipoprotein-deficient serum; MEM, mini- 
mum essential medium. 
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2. MATERIALS  AND METHODS 
2,1, Cells 
A segment of middle jejunum was taken at autopsy within 1 h after 
death. Small intestine pithelial cells (enterocytes) were isolated and 
maintained as previously described [3,4l. 
2,2. Lipoproteins 
High-density lipoproteins (HDL0 (d = 1,125-1,216 g/cm ~) were 
isolated from the blood plasma of healthy donors by sequential 
preparative ultracentrifugation [11], lodination was performed ac- 
cording to Bilheimer et al. [12], 
2.3. Antibodies 
The preparation and characterization f polyclonal anti-ape A.I 
and anti.ape A-II antibodies [13], and antibody against ape A-1-BP 
[9] has been described previously. 
2.4, Binding assay 
To determine the effect ofanti-A-i-BP antibodies on HDL interac- 
tion with enterocytes the incubation mixture containing 0,5 × 10 ~ cells, 
50/al lipoprotein-deticient serum (LDS), 250/ag non-immune rabbit 
IgG, indicated concentrations of anti-ape A-I-BP antibody, and min- 
imum essential medium (MEM, Flow, Ayrshire, UK) in a total volume 
of 250bd, was incubated in the wells of 24-well plates for 1 h at 370C 
in a CO,. incubator (5% CO:, 95% air) with shaking in an orbital 
shaker at 60 rpm, After pr=-incubation with antibody [t2Sl]HDL.~ was 
added to the incubation mixture (final concentration 5/.tg/ml), To 
determine non-specific binding, a 10-fold ex~ss of HDL.~ was added 
in parallel incubations. Tile mixture was incubated for a further 2 h 
under the same conditions, The amount of bound and degraded 
[~:SI]HDL~ was dctermin~ as previously described [3,4], 
To determine the effect of anti-ape A-I and anti.ape A-II antibodies 
on [J=~IIHDLa interaction with cells [ml]HDLa (2,5/tg) was incubated 
with indicated concentrations of antibodies or 250/.tg non-immune 
rabbit lgG (control incubations) inMEM (total volume 250,ul) for 1 
h at room temperature with shaking at 100 rpm, After pro-incubation, 
cells (0.5 x 106), LDS (50/tl) and MEM were addgd (total volume 0,5 
ml) and the mixture was incubated for a further 2 h under the same 
conditions, The amount of bound and degraded radioactivity was 
determined as described above. To test the effect of antibodies on 
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["Sl]HDL~ binding to cholesterol-loaded ¢~lls, cholesterol in the form 
of 1% ethanolic solution was added to the prc-incubated mixture to 
a final concentration f 60 pg/ml, and the mixture was incubated for 
1 h at 37"C. After pre-incubation cells were washed with 10 ml of 
MEM containing I mg/ml bovine serum albumin, and binding exper- 
iments were performed as described above. 
3. RESULTS 
3.1. Effect of anti-apo A-1 and anti.ape A-II on the inter- 
action of /ml]HDL3 with enterocytes 
To study the effect of antibodies pecific for two 
major apolipoproteins of HDL3 on [~:Sl]HDL~ interac- 
tion with human enterocytes [~"5I]HDL~ was pre-incu- 
bated with each antibody (50--300 ,ug/ml) or a mixture 
of the two. Treatment of [;2SI]HDL~ with anti-ape A-I 
and anti-ape A-1I resulted in a dose-dependent i hibi- 
tion of [t:5I]HDL~ binding to enterocytes by 20-30 and 
50%, respectively (Fig. 1). The degradation of 
[~"SI]HDL~ was reduced by 80%, i.e. down to the level 
of non-specific degradation. The non-specific binding 
and degradation accounted for 20-30% of the total and 
did not change after treatment of [~zSI]HDL~ with anti- 
bodies. Treatment of [°SI]HDL~ with non-immune rab- 
bit IgG (1 mg/ml) had no effect on its binding and 
Table I
Effect of anti-ape A-I, anti-ape A-li and anti-ape A-I-binding protein 
antibodies on [J2q]HDL~ interaction with human enteroeytes 
Additions [mI]HDL.~ binding (ng/mg cell protein) 
Non-cholesterol- Cholesterol- 
loaded cells loaded cells 
Experbnent 1 
None 54,5 +_ 3.1 69.0 "L-_ 3,3* 
Anti-ape A-I-BP 30.7 _ 3,1"* 48.1 +_ 5,5*** 
Anti-ape A-II 25,2 __ 9,1"* 22.1 _+ 7,3*** 
Experbl,ent H 
None 252.0 ~ 15.0 355,0 +_ 64.0* 
Anti-ape A-I 210.0 +_. 10.0"* 147.0 + 31.0"* 
Anti-ape A-II 38.0 ± 5,0"** 43,0 + 12.0"** 
Human enterocytes (0.5 x I06) were pre.incubated with no additions 
or with ape A-I-BP antibody (final concentration 200/zg/ml) in the 
presence or absence of cholesterol (final concentration 60/Jg/ml) for 
1 h at 37°C with shaking at 60 rpm. fiimultancously, [r I]HDL~ was 
pre-incubated with no additions or with anti-ape A-I antibody (final 
concentration 100/~g/ml) or anti-ape A-II (final co ~centration 100 
/~g/ml) for 1 h at room temperature. After pre-incubation cells were 
washed by centrifugation at 500 x g at room temperature for I 0 rain 
and resusp¢nd~ in 0.5 ml of media containing 10% LDS. pre.incu- 
bated [ml]HDL~ (final concentration 5 .ug/ml) and corresponding 
antibody in a final concentration identical to the pro.incubation mix- 
turn. The mixture was incubated for 2 h at 370C with shaking at 60 
rpm, Amount of hound [t:SI]HDL~ was determined as described in 
s=tion 2. Sp~ific binding (i.¢, total minus non-specific, measured in 
the presence of a 10-fold excess of unlabelled particles) is presented. 
Each value is the mean _+ $.E,M, of quadruplicate d terminations of 
a representative experiment. *P < 0.01 (vs. corresponding value with 
non-cholesterol-loaded c lls); **P < 0.01 (vs. no additions); ***P < 
0,001 (vs, no additions), 
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Fig, 1. Effect of anti-ape A-I and anti-ape A-II antibodies on 
[I:q]HDL3 interaction with human enterocytes, lJ2Si]HDL~ (2.5.ug) 
was pre.ineubated with indicated concentrations of anti-ape A-I (D.o) 
or anti-ape A-II (A,&) or 250/zg/ml non-immune rabbit IgG (con- 
trols) for 1 h at room temperature. After pre.incubation lipoprotein 
was added to cells (0.5 x 106. final volume 0,5 ml) and samples wcrc 
incubated for a further 2 h at 370C with shaking at 60 rpm. Amount 
of bound (open symbols) and degraded (filled symbols) [t2Sl]HDL~ was 
determined as described in section 2. Each point is the mean of two 
(A,&) or three (n,o) independent exl~rimcnts; each experiment was 
done in duplicate. 
degradation. Treatment of [t251]HDL~ with the mixture 
of both antibodies (50 pg/ml each) had no additional 
effect on its binding and degradation ( ot shown). 
3.2. Effect of anti-ape A-I-BP antibody on the interac- 
tion of [mI]HDLj with enterocytes 
To study the effect of antibody against ape A-I-BP 
on [t-'~I]HDL3 interaction with enterocytes cells were 
pre-incubated with different concentrations of these an- 
tibodies (5-200 pg/ml). To exclude non-sp~ific effects 
of IgG excess of non-immune rabbit Ig(3 (250/2g/ml) 
was added to the incubation mixtures (including con- 
trols), Comparison of control incubations with and 
without added IgG demonstrated that non-immune 
rabbit IgG (250 pg/ml) caused 40% inhibition of 
[~2q]HDL~ binding but had no eff~t on its degradation. 
Treatment of human enteroeytes with anti-ape A-I-BP 
antibody reduced [12SI]HDL~ binding and degradation 
by about 50% in a dose-dependent manner (Fig. 2). 
Non-specific binding and degradation did not change 
after treatment of cells with anti-ape A-1-BP antibody. 
3.3. Effect of anti-ape A-I.BP and anti.ape A-I and ape 
A-H antibodies on [I'~I]HDL~ binding to choles- 
terol-loaded enterocytes 
It was demonstrated previously that loading of en- 
terocytes with cholesterol upregulates [~2q]HDL~ bind- 
ing to these cells [4]. Treatment of cholesterol-loaded 
and non-cholesterol-loaded enterocytes with ape A-I- 
BP antibody decreased [t2SI]HDL~ binding by 30 and 
44%, respectively (Table I). Treatment of [~-'SI]HDI,~ 
with anti-ape A-I and anti-ape A-1I antibody also de- 
creased its binding to both cholesterol-loaded and non- 
cholesterol-loaded cells (Table I). 
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Fig, 2. Effect of anti-ape A-I-binding protein antibody on [mI]HDL~ 
interaction with human cnterocytcs. Human entcrocyt~ were pro- 
incubated with 1 mg/ml of rabbit non-immune IgO, 10% LDS and 
indicated concentrations f anti-ape A-I-BP for 1 h at 37°C with 
shaking at 60 rpm, Then, [t:Sl]HDL.t was added to a final concentra- 
tion of 5/~s/ml and incubated for a further 2h at 37°C with shaking 
at 60 rpm. Amount of bound (a) and degraded (A) [t~SllHDLs was 
determined as described in section 2. Specific binding and degradation 
(i,e. total minus non-six'title, measured in the presence of 10.fold 
0~¢¢ss of unlabelled particles) are pres¢nted. Each point is the mean 
of two independent exp¢rim¢nts; each ¢x~riment was done in 
duplicate. 
4. DISCUSSION 
If the association between HDL and cells includes a 
receptor-ligand interaction this implies that both lipo- 
protein and receptor possess pecific recognition sites. 
Several attempts have been undertaken to identify de- 
terminants in both HDL [5] and its putative receptor 
[7-10]. These studies have, however, not resulted in a 
consensus for the identities of specific determinants in- 
volved in this interaction. In the present work we have 
tried to address this question using antibodies against 
two potential ligands, ape A-I and ape A-II. and also 
against a potential receptor, an ape A-I-BP from 
human placenta [9]. 
We have shown that treatment of [~:SI]HDL~ with 
antibodies against apo A-I and ape A-II inhibits 
[:-Sl]HDL3 binding to both cholesterol-loaded and non- 
cholesterol-loaded human enterocytes. The effect of an- 
tibodies on[:-~I]HDL3 degradation was more pro- 
nounced than on its binding. This may be due to the 
interference ofthe binding of [t2SI]HDL~-antibody com- 
plex to FC receptors on the enterocytes c~t o the forma- 
tion of aggregates containing several [~:Sl]HDL~ parti- 
cles bound to the antibodies. Both anti-apoA-I and -ape 
A-II antibodies inhibited interaction of [t'-SI]HDL3 with 
human enterocytes. This could mean that both ape A-I 
and ape A-II may be determinants of HDL receptor. 
The distribution of hydrophobic, acidic and basic 
amino acids in the 1 l-mer, which is the main internal 
repeat unit of both ape A-I and ape A-II, shows a high 
degree of homology between these apolipoprotcins [14]. 
However, the possibility cannot be excluded that bind- 
ing of antibody to [:-SI]HDL~ may inhibit its interaction 
with the receptor due to steric interference. Our data are 
consistent with those reported by Fidge and Nestel [5]. 
Treatment of enterocytes with anti-ape A-I-BP inhib- 
ited [t:SI]HDL3 binding and degradation by 50%. More- 
over, in experiments with cholesterol-loaded ¢ntero- 
cytes only half of the additionally appearing binding 
sites were inhibited by treatment with antibody. This 
suggests that either ape A-I binding protein is only a 
part of the HDL receptor, or that antibodies have not 
fully masked the ¢pitopes involved in binding, 
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